PODD - NASDAQ
Insulet Corporation
$145.31
+1.4%Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
At a Glance
Live SnapshotInsulet Corporation Management Team
Ms. Ashley A. McEvoy
Chief Executive Officer, President & Director
Mr. Amit Guliani
Chief Technology Officer
Ms. Flavia H. Pease
Executive Vice President & Chief Financial Officer
Compensation
$53,083
Mr. Eric Benjamin
Executive Vice President & Chief Operating Officer
Compensation
$1,235,265
Ms. Ana Maria Chadwick
Executive Vice President, Chief Financial Officer & Treasurer
Compensation
$1,081,078
Mr. Eric Benjamin
Executive Vice President, Chief Product & Customer Experience Officer
Compensation
$1,235,265
Ms. Lauren Budden
Group Vice President, Chief Accounting Officer & Controller
Compensation
$826,359
Mr. Amit Guliani
Interim Chief Technology Officer & Group Vice President of Customer-Facing Software Engineering
Ms. Angela Geryak Wiczek
Senior Director of Corporate Communications
June Lazaroff
Senior Director of Investor Relations
Mr. John Wodick Kapples J.D.
Senior Vice President & General Counsel
Compensation
$1,055,380
Mr. Prem Singh
Senior Vice President of Global Operations
Insulet Corporation Insider Positioning
During the last 12 months, insiders have purchased $1.83M and sold $4.14M worth of PODD shares, resulting in $2.31M of net selling activity.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
6.3K
1.53M
1.9K
542.51K
+987K
+$987K
6-9 Months
962
299.88K
1.5K
516.73K
-217K
-$217K
9-12 Months
0
0.00
9.7K
3.08M
-3.1M
-$3.08M
Top Buyers
Mcevoy Ashley
Director, Officer: President And Ceo
$1.03M
Minogue Michael R
Director
$500K
Stonesifer Timothy C.
Director
$300K
Top Sellers
Benjamin Eric
Officer: Evp, Cpxo
$1.42M
Singh Prem
Officer: Svp, Global Operations
$1.37M
Frederick Wayne A.I.
Director
$543K
Manea Dan
Officer: Svp, Chief Hr Officer
$390K
Cousin Laetitia
Officer: Svp, Reg, Quality & Compliance
$278K
Insider Activity Analysis
Net Insider Sentiment
Negative insider sentiment with $2.31M net selling. Selling notably exceeds buying, warranting closer scrutiny of company fundamentals.
Buy/Sell Ratio
Weak buy/sell ratio. Selling significantly exceeds buying—monitor for potential fundamental concerns.
Insider Participation
5 insider sellers vs. 3 buyers. More insiders selling than buying suggests cautious or negative sentiment.
SEC Filings
PODD - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 06, 2026 | May 20, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 29, 2025 | May 22, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 09, 2024 | May 22, 2024 | 2024 | |
DEF 14A DEF 14A N/A | April 06, 2023 | April 06, 2023 | ||
DEF 14A DEF 14A 2022 N/A | April 12, 2022 | May 24, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 13, 2021 | May 27, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 13, 2020 | May 29, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | April 12, 2019 | May 30, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | April 06, 2018 | April 06, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | April 07, 2017 | April 07, 2017 | 2017 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.